Ctrl K
NTHI trades 222.6% below Wall Street's consensus target of $16.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes NTHI achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 1 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 3, 2026, Neonc Technologies Holdings, Inc. (NTHI) has a Wall Street consensus price target of $16.00, based on estimates from 1 covering analysts. With the stock currently trading at $4.96, this represents a potential upside of +222.6%. The company has a market capitalization of $129M.
Analyst price targets range from a low of $13.00 to a high of $20.00, representing a 44% spread in expectations. The median target of $15.00 differs from the mean, suggesting potential outlier estimates.
The current analyst consensus rating is Buy, with 1 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, NTHI trades at a trailing P/E of -1.5x. Analysts expect EPS to grow +38.6% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 NVCRNovocure Ltd | $2.1B | $17.83 | $26.00 | +45.8% | Buy | — | 15 |
 CLDXCelldex Therapeutics, Inc. | $2.6B | $39.48 | $62.63 | +58.6% | Buy | — | 19 |
 NKTRNektar Therapeutics | $2.4B | $72.74 | $150.00 | +106.2% | Buy | — | 33 |
 IMVTImmunovant, Inc. | $8.2B | $39.49 | $40.00 | +1.3% | Buy | — | 23 |
 ABBVAbbVie Inc. | $462.4B | $261.70 | $285.92 | +9.3% | Buy | 18.7x | 42 |
 MRKMerck & Co., Inc. | $374.5B | $151.64 | $154.93 | +2.2% | Buy | 55.2x | 37 |
 RGENRepligen Corporation | $9.8B | $172.94 | $152.00 | -12.1% | Buy | 83.9x | 24 |
 FATEFate Therapeutics, Inc. | $286M | $2.45 | $5.63 | +129.8% | Buy | — | 31 |
 KPTIKaryopharm Therapeutics Inc. | $41M | $1.79 | $14.17 | +691.6% | Buy | — | 20 |
 TMOThermo Fisher Scientific Inc. | $226.1B | $608.54 | $597.67 | -1.8% | Buy | 24.2x | 43 |
Quick answers to the most common questions about buying NTHI stock.
The consensus Wall Street price target for NTHI is $16, representing 222.6% upside from the current price of $4.96. With 1 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
NTHI has a consensus rating of "Buy" based on 1 Wall Street analysts. The rating breakdown is predominantly bullish, with 1 Buy/Strong Buy ratings. The consensus 12-month price target of $16 implies 222.6% upside from current levels.
NTHI's current price is $4.96 with a consensus target of $16 (222.6% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $20 for NTHI, while the most conservative target is $13. The consensus of $16 represents the median expectation. These targets typically reflect 12-month expectations.
NTHI is lightly followed, with 1 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 1 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month NTHI stock forecast based on 1 Wall Street analysts shows a consensus price target of $16, with estimates ranging from $13 (bear case) to $20 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on NTHI, with a "Buy" consensus rating and $16 price target (222.6% upside). 1 of 1 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
NTHI analyst price targets range from $13 to $20, a 44% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $16 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.